1st patient dosed in Phase 2 trial of Parkinson's therapy VTX3232
The first patient has been dosed in a Phase 2a trial of Parkinson's therapy VTX3232, an oral medication designed to reduce inflammation.| Parkinson's News Today
The first patient has been dosed in a Phase 2a trial of Parkinson's therapy VTX3232, an oral medication designed to reduce inflammation.| Parkinson's News Today
